Trega Biosciences Licenses iDEA(TM) Absorption Module to Tibotec Group;Trega's Drug Discovery Products Appeal to Emerging Pharmaceutical Company
SAN DIEGO, Dec. 13 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA), a company focused on commercializing technologies and products for accelerating drug discovery and development, today announced that Tibotec Group N.V., an emerging pharmaceutical company headquartered in Mechelen, Belgium, has licensed Trega's iDEA(TM) Predictive ADME Simulation System for absorption. Tibotec will utilize the iDEA(TM) absorption module in its drug discovery activities, which are currently focused in the area of HIV and AIDS. Tibotec was granted a multi-year site license to the iDEA(TM) absorption module and has an option to license the iDEA(TM) metabolism module which is scheduled for release at the end of this year. Financial terms were not disclosed.
"We are very excited about gaining access to Trega's iDEA(TM) Predictive ADME Simulation System, because we believe that in silico technologies will assist our scientists in accelerating the drug discovery and development process," said Tibotec chief executive officer Dr. Rudi Pauwels.
"Our licensing agreement with Tibotec reflects the expanding market for our iDEA(TM) Predictive ADME Simulation System among smaller progressive pharmaceutical and biotechnology companies. These modules have been designed to accelerate and refine current drug discovery efforts and can offer improved timelines to a wide range of pharmaceutical and biotechnology companies," said Michael G. Grey, president and chief executive officer. "We view the expansion of the market for our products as an indication of the success our initial licensees have had with our products which we believe can be duplicated across the biopharmaceutical industry."
The iDEA(TM) Predictive ADME (absorption, distribution, metabolism, excretion) Simulation System for absorption is an efficient, validated and highly predictive in silico solution developed in conjunction with five prominent pharmaceutical companies. The absorption module was constructed to simulate the physiological process of drug absorption, and incorporates human physiological parameters. The model is trained with a proprietary database of in vitro and human in vivo pharmacokinetic data for selected drugs and drug candidates, including many that failed in the development process. This training set of compounds is unique in that it represents a very diverse set of drug properties. Trega plans to complete a metabolism module at the end of this year and subsequently develop additional modules that will enable the complete prediction of bioavailability.
Tibotec is an emerging pharmaceutical company that has established a powerful and effective platform for rapidly discovering and developing superior drugs for unmet medical needs. The Company is initially focusing its efforts on HIV and AIDS. Tibotec has created this platform by combining leading edge, proprietary drug discovery tools with a multidisciplinary and integrated approach to the drug discovery and development process. Tibotec is developing novel anti-HIV drugs that address the serious problems of drug resistance, compliance and side effects. Tibotec was founded in 1994 and has over 150 staff worldwide. The Company has three sites: Mechelen, Belgium; Rockville, Maryland, USA; and Dublin, Ireland. For more information on Tibotec please see the website at tibotec.com.
Trega Biosciences, Inc. (Nasdaq: TRGA) is a premier provider of products that accelerate and improve drug discovery through its iDiscovery(TM) technologies linking biology and chemistry with information technologies. Trega's iDEA(TM) family of information-based models simulate, in silico, how drug candidates will be processed in the body, thereby enabling selection of those with optimal characteristics for clinical development. Together with its iDEA(TM) products, Trega's ChemFolio(R) libraries of information-enhanced small molecules are designed to facilitate the identification and optimization of drug candidates. For additional information on Trega, please visit our Web site at trega.com.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including whether this transaction will be successful, any additional licenses, alliances or other transactions will be agreed to, formed or expanded, whether any such transactions will be successful, the impact of competitive products and pricing, and other risks detailed from time to time in Trega's Securities and Exchange Commission filings. These forward-looking statements represent Trega's judgment as of the date of this release. Trega disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE Trega Biosciences, Inc.
CO: Trega Biosciences, Inc.; Tibotec Group N.V.
ST: California, Belgium
IN: MTC BIO
SU: LIC
12/13/2000 08:01 EST prnewswire.com |
